Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
June 01, 2023 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference
May 22, 2023 13:15 ET
|
Aerovate Therapeutics, Inc.
Direct delivery of imatinib to the lungs in nonclinical species demonstrated increased lung exposure compared with oral or IV dosing Formulation impacted lung exposure with dry powder demonstrating...
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
May 15, 2023 16:05 ET
|
Aerovate Therapeutics, Inc.
Topline Phase 2b data now expected in the second quarter of 2024 for the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH)More than 100 sites activated...
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
March 29, 2023 16:50 ET
|
Aerovate Therapeutics, Inc.
Progress continued on the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Expanded intellectual property portfolio with four issued patents in 2022 ...
Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
March 02, 2023 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
January 23, 2023 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
November 17, 2022 07:45 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
November 14, 2022 07:45 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022
October 18, 2022 08:00 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today presents the design of IMPAHCT (Inhaled iMatinib for Pulmonary Arterial Hypertension Clinical...
Aerovate Therapeutics Announces Second Quarter 2022 Financial Results
August 15, 2022 07:50 ET
|
Aerovate Therapeutics, Inc.
WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...